Skip to main content
Intermediate Technical IVT

targetable alteration

Genetic variant with available FDA-approved or investigational therapies that specifically address the molecular abnormality.

Full Definition

A targetable alteration is a specific genetic variant, gene fusion, or molecular abnormality for which effective targeted therapeutic agents exist or are in clinical development. These alterations include oncogenic mutations, gene amplifications, and chromosomal rearrangements that drive cancer growth and can be specifically inhibited by small molecules, monoclonal antibodies, or other precision therapies. The determination of targetability depends on current therapeutic options, clinical evidence, and regulatory approval status. Clinical reports must clearly distinguish between targetable alterations with established therapies versus those with experimental treatments.

Usage

Usage note: Preferred over 'actionable' in clinical documentation; specify therapy availability level when possible.

In Context

  • "Genomic testing identified three targetable alterations including an EGFR exon 19 deletion." — Molecular tumor board report
  • "The patient's tumor harbored no targetable alterations based on current therapeutic options." — Precision oncology consultation

Also known as

actionable variant druggable mutation

Contrasted with

non-targetable alteration passenger mutation

Don't confuse with

pathogenic variant clinically significant variant

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON